Skip to main content

Table 5 UGT1A/DPYD polymorphisms and clinical response

From: Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis

Genotype

Single IRI Â± targeted therapy

IRI + fluorouracill Â± targeted therapy

 

First line treatment

≧Second line treatment

First line treatment

≧Second line treatment

ORR

P value

DCR

P value

ORR

P value

DCR

P value

ORR

P value

DCR

P value

ORR

P value

DCR

P value

Sex

 Male

0/1 (0.0%)

 

1/1 (100.0%)

 

0/29 (0.0%)

 

18/29 (62.1%)

 

17/56 (30.4%)

 

49/56 (87.5%)

 

39/295 (13.2%)

 

235/295 (79.7%)

 

 Female

1/3 (33.3%)

1.000

2/3 (67.7%)

1.000

4/34 (11.8%)

0.118

19/34 (55.9%)

0.619

12/33 (36.4%)

0.559

29/33 (87.9%)

0.958

23/183 (12.6%)

0.837

141/183 (77.0%)

0.498

Age

≦65y

1/3 (33.3%)

 

2/3 (66.7%)

 

4/42 (9.5%)

 

28/42 (66.7%)

 

28/80 (35.0%)

71/80 (88.8%)

 

56/398 (14.1%)

317/398 (79.6%)

 >65y

0/1 (0.0%)

1.000

1/1 (100.0%)

1.000

0/21 (0.0%)

0.292

9/21 (42.9%)

0.070

1/9 (11.1%)

0.216

7/9 (77.8%)

0.343

6/80 (7.5%)

0.11

59/80 (73.8%)

0.24

Primary tumor location

 Left-side colorectum

1/3 (33.3%)

 

2/3 (66.7%)

 

3/43 (7.0%)

 

27/43 (62.8%)

 

20/60 (33.3%)

54/69 (90.0%)

 

47/362 (13.0%)

289/362 (79.8%)

 Right-side colon

0/1 (0.0%)

1.000

1/1 (100.0%)

1.000

1/20 (5.0%)

1.000

10/20 (50.0%)

0.337

9/29 (31.0%)

0.828

24/29 (82.8%)

0.331

15/116 (12.9%)

0.988

87/116 (75.0%)

0.269

UGT1A1*6

 G/G

1/4 (25.0%)

 

3/4 (75.0%)

 

3/46 (6.5%)

 

28/46 (60.9%)

 

17/54 (31.5%)

 

49/54 (90.7%)

 

42/310 (13.5%)

 

239/301 (77.1%)

 

 G/A

0/0 (0.0%)

 

0/0 (0.0%)

 

1/15 (6.7%)

 

7/15 (46.7%)

 

9/31 (29.0%)

 

25/31 (80.6%)

 

16/145 (11.0%)

 

119/145 (82.1%)

 

 A/A

0/0 (0.0%)

NA

0/0 (0.0%)

NA

0/2 (0.0%)

0.932

2/2 (100.0%)

0.302

3/4 (75%)

0.175

4/4 (100.0%)

0.295

4/23 (17.4%)

0.615

18/23 (78.3%)

0.483

UGT1A1*27

 C/A

0/0 (0.0%)

 

0/0 (0.0%)

 

3/43 (7.0%)

 

28/43 (65.1%)

 

2/3 (66.7%)

 

2/3 (66.7%)

 

54/387 (14.0%)

 

313/387 (80.9%)

 

 C/C

1/2 (50.0%)

NA

2/2 (100.0%)

NA

0/0 (0.0%)

NA

0/0 (0.0%)

NA

26/84 (31.0%)

0.193

74/84 (88.1%)

0.272

0/7 (0.0%)

0.600

6/7 (85.7%)

0.747

UGT1A1*28

 TA6/TA6

1/3 (33.3%)

 

2/3 (66.7%)

 

4/48 (8.3%)

 

29/48 (60.4%)

 

15/59 (25.4%)

 

52/59 (88.1%)

 

53/373 (14.2%)

 

293/373 (78.6%)

 

 TA6/TA7,TA7/TA7

0/1 (0.0%)

1.000

1/1 (100.0%)

1.000

0/15 (0.0%)

0.564

8/15 (53.3%)

0.627

14/30 (46.7%)

0.043

26/30 (86.7%)

0.842

9/105 (8.6%)

0.129

83/105 (79.0%)

0.913

UGT1A7

                

  UGT1A7*1/*1,*1/*2,*2/*2

1/2 (50.0%)

 

2/2 (100.0%)

 

3/32 (9.4%)

 

20/32 (62.5%)

 

12/47 (25.5%)

 

42/47 (89.4%)

 

35/241 (14.5%)

 

194/241 (80.5%)

 

  UGT1A7*1/*3,*2/*3,*3/*3

0/0 (0.0%)

0.558

0/0 (0.0%)

NA

0/11 (0.0%)

0.558

8/11 (72.7%)

0.539

15/38 (39.5%)

0.17

32/38 (84.2%)

0.482

19/153 (12.4%)

0.554

125/153 (81.7%)

0.767

UGT1A9*22

 T9/T9

0/0 (0.0%)

 

0/0 (0.0%)

 

0/8 (0.0%)

 

5/8 (62.5%)

 

6/13 (46.2%)

 

11/13 (84.6%)

 

5/71 (7.0%)

 

61/71 (85.9%)

 

 T9/T10,T10/T10

1/2 (50.0%)

1.000

2/2 (100.0%)

NA

3/35 (8.6%)

1.000

23/35 (65.7%)

0.863

21/72 (29.2%)

0.226

63/72 (87.5%)

0.776

49/323 (15.2%)

0.071

258/323 (79.9%)

0.241

DPYD*5

 A/A

NA

 

NA

 

NA

 

NA

 

8/41 (19.5%)

 

34/41 (82.9%)

 

32/211 (15.2%)

 

174/211 (82.5%)

 

 A/G,G/G

NA

NA

NA

NA

NA

NA

NA

NA

19/44 (43.2%)

0.019

40/44 (90.9%)

0.273

22/183 (12.0%)

0.365

145/183 (79.2%)

0.415

DPYD c.1896 T > C

 T/T

NA

 

NA

 

NA

 

NA

 

24/69 (34.8%)

 

60/69 (87.0%)

 

42/314 (13.4%)

 

254/314 (80.9%)

 

 T/T,T/C

NA

NA

NA

NA

NA

NA

NA

NA

3/16 (18.8%)

0.215

14/16 (87.5%)

0.953

12/80 (15.0%)

0.706

65/80 (81.3%)

0.942

  1. IRI: Irinotecan; ORR: Objective response rate; DCR: Disease control rate; Tumor location: Left-side colorectum included splenic flexure, descending colon, sigmoid colon and rectum; Right-side colon included cecum, ascending and transverse colon [18]; NA: Non-acquired